Nancy E. Lane, MD is an Endowed Professor of Medicine, Rheumatology, and Aging Research, Director for the Center for Musculoskeletal Health, Director of the K12 NIH Building Interdisciplinary Research Careers in Women's Health (BIRCWH), and Principal Investigator of the NIH funded Program on Sex Differences in Musculoskeletal Diseases Across the Lifespan at the University of California at Davis School of Medicine where she has served for the past 8 years.
Dr. Lane is an internationally recognized scientist in the fields of both osteoporosis and osteoarthritis. Her translational research team has been instrumental in defining the role of glucocorticoids in bone fragility including their effects on cell stress and vulnerable cell populations including osteocytes. As a faculty member at the University of California at San Francisco, she pioneered a seminal clinical trial to demonstrate that daily injections of the hormone PTH could reverse glucocorticoid induced osteoporosis. After transitioning to U.C. Davis, she a developed a novel compound to direct stem cells to the bone to grow new bone and treat osteoporosis. In addition she has uncovered novel genetic variations that predispose individuals to osteoarthritis and has studied novel treatments for osteoarthritis. She organized and directs an NIH funded junior faculty grant writing workshop that has taught over 300 junior faculty in musculoskeletal medicine grant writing skills that has resulted in a 45% success rate in applicants receiving research grants (2006-present).
Dr. Lane has been recognized by the University, her medical residents, subspecialty fellows, and by her faculty peers as an outstanding mentor with the UC Davis Dean's Award for Scientific Mentoring (2008). Her research accomplishments have been recognized by the UC Davis School of Medicine Dean's Team Science Award (2012), the American College of Rheumatology for the Oscar Gluck Memorial Lecture for outstanding work in Osteoporosis (2011), the Remodeling in Bone “RIB Award” by the International Society of Bone and Mineral Research (2012), her election as a Master of the American College of Physicians (2012) and David Trentham Lectureship and Women in Medicine Lectureship at Harvard Medical School (2013).. She is also recipient of the Bone and Joint Decade Outstanding Achievement Award for developing a mentoring program in grant writing (2009).
Dr. Lane was President of the Board of the United States Bone and Joint Decade (2006-2008), co-led the International Bone and Joint Decade Conference in Washington DC (2010),was elected and serves on the council of the American Society of Bone and Mineral Research (2010-2013), and the Orthopedic Research Society.
Dr. Lane is on the editorial boards of Nature Reviews Rheumatology, Rheumatology (Associate Editor), Seminars in Arthritis and Rheumatism (Associate Editor), Co-editor Arthritis and Rheumatism (2005-2010), Journal of Rheumatology, She was elected to the Association of American Physicians (2006), has been named Best Doctors in America annually since 2004, and continues to have an active rheumatology practice.
San Francisco, California
San Francisco, California
American Board of Internal Medicine, 1983
Select Recent Publications:
Wei Yao, Min Guan, Junjing Jia, Weiwei Dai, Yu-An E. Lay, Sarah Amugongo, Ruiwu Liu, David Olivos, Kit Lam, Jan Nolta, Diana Olvera, Robert O. Ritchie, Nancy E. Lane. Reversing Bone Loss by Directing Mesenchymal Stem Cells to the Bone. Stem Cell (in press April 2013)
Jia J, Yao W, Amugongo S, Lay YE, Shahnazari M, Cheng Z, Olvera D, Ritchie RO, Alliston T, Lane NE. Prolonged Alendronate Treatment prevent the decline in serum TGFB1 levels but reduce cortical bone strength following long-term estrogen deficiency. Bone. 2013 Jan;52(1):424-32
Min Guan, Wei Yao, RuiwuLiu, Kit S. Lam, Jan Nolta, Junjing Jia, Brian Panganiban, Liping Meng, Ping Zhou, Mohammad Shahnazari, Robert O Ritchie, Nancy E Lane. Directing mesenchymal stem cells to bone to augment bone formation and increase bone mass. Nat Med. 2012 Feb 5;18(3):456-62.
Domino SE, Bodurtha J, Nagel JD; BIRCWH Program Leadership. Interdisciplinary research career development: building interdisciplinary research careers in women's health program best practices. J Womens Health (Larchmt). 2011 Nov;20(11):1587-601.
Jia J, Yao W, Guan M, Dai W, Shahnazari M, Kar R, Bonewald L, Jiang JX, Lane NE. Glucocorticoid dose determines osteocyte cell fate. FASEB J. 2011 Oct;25(10):3366-76.
Lane NE,Schnitzer TJ, Birbara CA, Masoud Mokhtarani, Shelton DL, Smith MD, Brown MT. Efficacy and safety of anti-nerve growth antibody, tanezumab in the treatment of moderate to severe pain due to osteoarthritis of the knee. N Engl J Med 2010 363:1521-1531.
Lane NE. Clinical practice. Osteoarthritis of the hip. N Engl J Med. 2007 Oct 4;357(14):1413-21.
Lane NE, Lian K, Nevitt MC, Zmuda JM, Lui L, Li J, Wang J, Fontecha M, Umblas N, Rosenbach M, de Leon P, Corr M. Frizzled-related protein variants are risk factors for hip osteoarthritis. Arthritis Rheum. 2006; 54 (4): 1246-1254.
Lane NE, Armitage GC, Loomer P, Hseih S, Majumdar S, Wang HY, Jeffcoat M, Munoz T. Bisphosphonate therapy improves the outcome of conventional periodontal treatment: results of a 12-Month, Randomized, Placebo-Controlled Study. J Periodontol. 2005; 76(7):1113-22.
Lane NE, Pierini E, Modin G, Sanchez S, Arnaud CD. Bone mass continues to increase after parathyroid hormone treatment is stopped in osteoporotic women on low dose corticosteroids and hormone replacement. Journal of Bone and Mineral Research. 2000; 15(5):944-951.